(Q77333549)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9748496%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

review article

1 reference

title

Clinical applications of quinolones (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9748496%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

author name string

D C Hooper

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9748496%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

language of work or name

English

0 references

publication date

1 October 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9748496%20AND%20SRC:MED&resulttype=core&format=json

Biochimica et Biophysica Acta

4 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9748496%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

volume

1400

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9748496%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

issue

1-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9748496%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

page(s)

45-61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9748496%20AND%20SRC:MED&resulttype=core&format=json

Fluoroquinolone antimicrobial agents

4 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Susceptibility of mycoplasmas to antimicrobial agents: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Rote of the quinolones in the treatment of legionellosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

1 reference

7 January 2021

In-vitro activity of levofloxacin (l-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Sparfloxacin and other new fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Mechanism of action of quinolones against Escherichia coli DNA gyrase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Mode of action of the quinolone antimicrobial agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Pharmacokinetics and pharmacodynamics of newer fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Quinolone antibacterials. An update of their pharmacology and therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

The quinolones. An overview of their pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

The clinical pharmacokinetics of levofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Ofloxacin clinical pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Effect of quinolone antimicrobials on theophylline pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Placement of alkyl substituents on the C-7 piperazine ring of fluoroquinolones: dramatic differential effects on mammalian topoisomerase II and DNA gyrase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Antagonism of GABAA receptors by 4-quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Photoreactions with a fluoroquinolone antimicrobial: evening versus morning dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Lack of quinolone-induced arthropathy in children

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Torsades de pointe probably related to sparfloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Norfloxacin: review of safety studies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Ciprofloxacin versus trimethoprim-sulfamethoxazole: treatment of community-acquired urinary tract infections in a prospective, controlled, double-blind comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Management of urinary tract infections in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Single dose quinolone treatment in acute uncomplicated urinary tract infection in women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Single-dose enoxacin compared with 3-day treatment for urinary tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Treatment of pyelonephritis in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Ciprofloxacin and co-trimoxazole in urinary tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

In vitro activity of nine fluoroquinolone antibiotics against 200 strains of enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

The fluoroquinolones exert a reduced rate of kill against Enterococcus faecalis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Development of resistance during antibiotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Use of quinolones in treatment of prostatitis and lower urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Quinolones in sexually transmitted diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Comparison of ciprofloxacin and ceftriaxone as single-dose therapy for uncomplicated gonorrhea in women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Comparison of ofloxacin and ceftriaxone in the treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing strains

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Comparative efficacy and safety of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Quinolone-resistant Neisseria gonorrhoeae in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Azithromycin as a cost-effective treatment for nongonococcal urethritis in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Treatment of genital chlamydial infection with ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non-gonococcal urethritis in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

A prospective randomized trial of ofloxacin vs. doxycycline in the treatment of uncomplicated male urethritis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Use of quinolones in the treatment of gastrointestinal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Treatment of traveler's diarrhea with ciprofloxacin and loperamide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Ciprofloxacin- and azithromycin-resistant Campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

High-Level Quinolone Resistance in Clinical Isolates of Campylobacter jejuni

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Ciprofloxacin for treatment of severe typhoid fever in children

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Treatment of typhoid fever with ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Emergence of nalidixic acid resistant Shigella dysenteriae type 1 in Thailand: an outbreak associated with consumption of a coconut milk dessert.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Detection of 4-quinolone resistance mutation in gyrA gene of Shigella dysenteriae type 1 by PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Therapy of penicillin- and cephalosporin-resistant pneumococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Fluoroquinolone antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Sequential intravenous/oral therapy with ciprofloxacin in severe infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Parenteral Followed by Oral Ofloxacin for Nosocomial Pneumonia and Community-acquired Pneumonia Requiring Hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Ciprofloxacin-resistant Pseudomonas.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Mycobacteria and the new quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Quinolones and osteomyelitis: state-of-the-art.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Ofloxacin versus parenteral therapy for chronic osteomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Oral antibiotic therapy for uncomplicated bacterial skin infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Assessment and management of foot disease in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Long-term prophylaxis with norfloxacin versus nitrofurantoin in women with recurrent urinary tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Quinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Patients: Effect of Augmented Gram-Positive Activity on Infectious Morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Epidemiology of the colonization of inpatients and outpatients with ciprofloxacin-resistant coagulase-negative staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Evaluation of single-dose ciprofloxacin in the eradication of Neisseria meningitidis from nasopharyngeal carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Mechanisms of resistance to quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Repressor mutations in the marRAB operon that activate oxidative stress genes and multiple antibiotic resistance in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Active efflux mechanisms for antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

New mechanisms of bacterial resistance to antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Epidemiologic typing of Staphylococcus aureus by DNA restriction fragment length polymorphisms of rRNA genes: elucidation of the clonal nature of a group of bacteriophage-nontypeable, ciprofloxacin-resistant, methicillin-susceptible S. aureus isolat

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988-1994: the emergence of decreased susceptibility to the fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Emergence of in vitro resistance to fluoroquinolones in Neisseria gonorrhoeae isolated in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Epidemiology of ciprofloxacin resistance among patients with methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Quinolone resistance and Campylobacter species

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

Increasing resistance of Neisseria gonorrhoeae in west and central Africa. Consequence on therapy of gonococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: epidemiology and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2898%2900127-4

7 January 2021

10.1016/S0167-4781(98)00127-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9748496%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference